PARP Inhibition | PARP Inhibitor Review
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells: Trends in Cell Biology
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect
JCM | Free Full-Text | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers | HTML
A decade of clinical development of PARP inhibitors in perspective - Annals of Oncology
PARP inhibitor - Wikipedia
Cancers | Free Full-Text | PARP Inhibitors in Melanoma—An Expanding Therapeutic Option? | HTML
PARP inhibitor resistance: the underlying mechanisms and clinical implications | Molecular Cancer | Full Text
PARP Inhibitors: Where Are We in 2020 and What's Coming Next?
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care? - ppt download
Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Dual mechanism of action of PARPi. Notes: Olaparib inhibits parylation... | Download Scientific Diagram
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells: Trends in Cell Biology
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | SpringerLink
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance | Experimental & Molecular Medicine
Effects of pharmacologic PARP inhibition in B16F10 melanoma cells.... | Download Scientific Diagram
Role of PARP Inhibitors in BRCA-Related Malignancies
PARP inhibitors in cancer treatment | OncologyPRO
PARP inhibitor combination therapy. | Semantic Scholar
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance | Bentham Science
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
PARP inhibitors: Synthetic lethality in the clinic
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
